SLRN (acelyrin.com) Market Value to Book Value Ratio

Acelyrin, Inc. (SLRN) relies on patent-protected developments to combat immune pathologies, although clinical trial uncertainty and high R&D expenses create certain risks. Meanwhile, a solid liquidity reserve guarantees financial stability. The GURU.Markets portal provides this chart, where the price-to-book ratio helps identify speculative deviations, and the value of 0.56 characterizes this level.

SLRN ACELYRIN Inc.: Market Value to Book Value in the range 02/21/2024 - 05/31/2025

Financial and market metric breakdowns for Acelyrin Inc. (SLRN)

- price and consensus price forecast:
Price Chart Acelyrin, Inc.|SLRN - Broker Consensus Forecast
- market capitalization data:
Market Value ACELYRIN, Inc.|SLRN - Full Business Value
- book capitalization data:
Book Value per Share ACELYRIN|SLRN - Accounting Value of Company|Market Capitalization to Book Value Ratio acelyrin.com|SLRN - Company Total Assets
- debt and liquidity data:
Debt to Equity Acelyrin, Inc.|SLRN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity ACELYRIN, Inc.|SLRN - Company Total Debt|Debts to Book Capitalization ACELYRIN, Inc.
Initial company analysis:Acelyrin, Inc. - SLRN

Acelyrin, Inc. (SLRN) innovative developments in the therapy of inflammatory diseases and its patent protection establish the potential for future cash flows. These expectations transform net assets into market value via the mvsbcap_co coefficient. This metric measures the stock price premium over book capital, reflecting market confidence in intangible assets. A value exceeding one indicates a high valuation of intellectual capital. The shift in this confidence is reflected in the change of the market-to-book value ratio.

Main competitors

Market Value to Book Value Ratio Haleon plc|KVUE (kenvue.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Verona Pharma VRNA|Market Capitalization to Net Assets Jyong Biotech Limited|Ligand Pharma (LGND) - Market Capitalization to Book Value Ratio|Market Value to Book Value Amneal Corp (AMRX)|Market Capitalization to Book Value Ratio PRGO (Perrigo Company plc)|alvotech.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Liquidia (LQDA)|GLPG: Market Value to Book Value|ANIP (ANI Pharma) - Market Value to Book Value Ratio|Afrezza (MNKD) - Market Cap to Net Assets Ratio|AMPH (Amphastar Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pacira.com (PCRX)|ARS Pharmaceuticals, Inc. (SPRY) - Market Cap to Net Assets Ratio|Market Value to Book Value TBPH (Theravance Biopharma Inc)|AQST: Market Value to Book Value Ratio|SCPH - Market-to-Book Ratio|Market Cap to Net Assets Ratio Tectonic TECX|TNXP - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio sxtchina.com SXTC|Eupraxia Pharmaceuticals Inc. (EPRX) - Market Value to Book Value|Market Capitalization to Book Value Ratio BHST (BioHarvest)|Market-to-Book Ratio EXOZ|Oramed Pharmaceuticals (ORMP) - Market Value to Book Value Ratio|Market Value to Book Value enterabio.com (ENTX)|Market Capitalization to Book Value Ratio HYFT (MindWalk Holdings Inc.)|Market Capitalization to Book Value Ratio ABVC BioPharma Inc. ABVC|CPIX: Market Capitalization to Book Value Ratio|QNTM - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio FGEN|TELO (telomirpharma.com) - Market-to-Book Ratio|Market Value to Book Value Ratio Rani Therapeutics Holdings|Market Value to Book Value Ratio Synergy CHC Corporation (SNYR)|Rallybio Corporation - Market Cap to Net Assets Ratio|Market-to-Book Ratio LEXX (lexariabioscience.com)|Market Value to Book Value Ratio Pulmatrix, Inc.|Market Value to Book Value Pheton Holdings Limited PTHL|Market Capitalization to Book Value Ratio APM (Aptorum)|LYRA: Market Capitalization to Book Value|Market Value to Book Value Ratio Impact BioMedical|Capitalization to Book Value Ratio TNF Pharmaceuticals, Inc.|YCBD - Market Cap to Net Assets Ratio|Market Value to Book Value painreform.com|CYTO (Altamira Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value LIPO (Lipella Pharmaceuticals Inc)|OPTN - Market Value to Book Value Ratio|Capitalization to Book Value Ratio Pieris Pharma PIRS|PROC: Market Capitalization to Book Value Ratio|petrospharma.com (PTPI) - Market Cap to Net Assets Ratio|Qilian International Holding - Market Cap to Net Assets Ratio|TFFP (TFF Pharmaceuticals Inc.) - Market Capitalization to Book Value